Egetis Therapeutics Full Year 2024 Earnings: Misses Expectations

Egetis Therapeutics (STO:EGTX) Full Year 2024 Results

Key Financial Results

• Net loss: kr343.6m (loss widened by 5.1% from FY 2023).
• kr1.12 loss per share.

EGTX Products In Clinical Trials

• Phase II: 2.

EGTX Post-Clinical Trial Products

• Pre-registration: 1.

All figures shown in the chart above are for the trailing 12 month (TTM) period

Egetis Therapeutics Revenues and Earnings Miss Expectations

Revenue missed analyst estimates by 19%. Earnings per share (EPS) also missed analyst estimates by 20%.

In the last 12 months, the only revenue segment was Emcitate contributing kr46.1m. The largest operating expense was Research & Development (R&D) costs, amounting to kr146.2m (39% of total expenses). Explore how EGTX's revenue and expenses shape its earnings.

Looking ahead, revenue is forecast to grow 65% p.a. on average during the next 3 years, compared to a 19% growth forecast for the Biotechs industry in Sweden.

Performance of the Swedish Biotechs industry.

The company's shares are up 3.0% from a week ago.

Risk Analysis

Before we wrap up, we've discovered 3 warning signs for Egetis Therapeutics that you should be aware of.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.